The humoral response involves interaction of B cells with antigen (Ag) and their differentiation into antibody- secreting plasma cells. The secreted antibody (Ab) binds to the antigen and facilitates its clearance from the body. The cell-mediated responses involve various subpopulations of T cells that recognize antigen presented on self-cells. Helper T cells respond to antigen by producing cytokines. Cytotoxic T cells respond to antigen by developing The Immune Response
33
Embed
The humoral response involves interaction of B cells with antigen (Ag) and their differentiation into antibody-secreting plasma cells. The secreted antibody.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
The humoral response involves interaction of B cells with antigen (Ag) and their differentiation into antibody-secreting plasma cells. The secreted antibody (Ab) binds to the antigen and facilitates its clearance from the body.
The cell-mediated responses involve various subpopulations of T cells that recognize antigen presented on self-cells. Helper T cells respond to antigen by producing cytokines. Cytotoxic T cells respond to antigen by developing into cytotoxic T lymphocytes (CTLs), which mediate killing of altered self-cells (e.g., virus-infected cells).
The Immune Response
The MHC class I pathway
Antigen Presenting Cell
Proteasome
Antigen
Peptides
ER
MHC I TCD8+
T-cell epitope
Identifying of T-cell epitopes is important for development of peptide-based vaccines, evaluation of subunit vaccines, diagnostic development
The immunoglobulin fold
Common Structures - Both the antibodies of the humoral response and the molecules involved in the cellular response (antibody, TCR, most CD [cell surface molecules expressed on various cell types in the immune system]) contain elements of common structure.
The domains in these molecules are built on a common motif, called the immunoglobulin fold, in which two anti-parallel sheets lie face to face. This structure probably represents the primitive structural element in the evolution of the immune response. The immunoglobulin fold is also found in a number of other proteins.
Epitope, or antigenic determinant, is defined as the site of an antigen recognized by immune response
molecules (antibodies, MHC, TCR)
T cell epitope – a short linear peptide or
other chemical entity (native or
denatured antigen) that binds MHC
(class I binds 8-10 ac peptides; class II
binds 11-25 ac peptides) and may be
recognized by T-cell receptor (TCR).
T cell recognition of antigen involves
tertiary complex “antigen-TCR-MHC”. MHC class I
T-Cell
Receptor
VV
Xenoreactive Complex AHIII 12.2 TCR bound to P1049 (ALWGFFPVLS) /HLA-A2.1
-2-Microglobulin
Complex Of A Human TCR, Influenza HA Antigen Peptide (PKYVKQNTLKLAT) and MHC Class II
T-Cell
Receptor
V V
MHC
class II
MHC
class II
1fyt 1lp9
Igg2A Intact Mouse Antibody - Mab231 (PDB ID 1igt)
Fc fragment
Fab fragment
Fv fragmentVH
VL
CH
CL
Heavy chain
Light chain
Igg2A Intact Mouse Antibody - Mab231 (PDB ID 1igt)
Fc fragment
Fab fragment
Fv fragmentVH
VL
CH
CL
Heavy chain
Light chain
B cell epitope – a site on B cell epitope – a site on the surface of the the surface of the antigen structure that antigen structure that binds antibody binds antibody molecule.molecule. Protein antigens usually Protein antigens usually contain both sequential (or contain both sequential (or continues, continues, they could work as they could work as epitopes even when a protein epitopes even when a protein is denaturedis denatured) and ) and nonsequential (discontinues nonsequential (discontinues or conformational) epitopes. or conformational) epitopes.
B cell recognition of antigen B cell recognition of antigen involves binary complex involves binary complex “native antigen-membrane “native antigen-membrane immunoglobulin”.immunoglobulin”.
Different antibody recognize Different antibody recognize different epitopes.different epitopes.
Most of the surface of a Most of the surface of a globular protein is potentially globular protein is potentially antigenic.antigenic.
magenta,magenta, blue,blue, orangeorange) and two ) and two conformational epitopes (conformational epitopes (yellowyellow, , pinkpink).).
HIV-1 envelope protein gp120 core complexed with CD4 and a neutralizing human antibody 17b
The entry of HIV into cells requires the sequential interaction of the viral exterior envelope glycoprotein, gp120, with the CD4 glycoprotein and a chemokine receptor on the cell surface. These interactions initiate a fusion of the viral and cellular membranes. Although gp120 can elicit virus-neutralizing antibodies, HIV eludes the immune system. Antibody 17b
(Fab fragment)
HIV-1 envelope protein gp120 (core fragment)
CD4 (N-terminal two domain fragment)
17b epitope
PDB: 1gc1
17b epitope is comprised of four discontinuous -strands.
B cells and T cells recognize different epitopes of the same protein antigen
T cell epitope
Denatured antigen
Linear peptide 8-30 ac
Internal (often)
Binding to T cell receptor:
Kd 10-5 – 10-7 M (low affinity)
Slow on-rate, slow off-rate (once bound, peptide may stay associated for hours to many days)
B cell epitope
Native or denatured (rare) antigen
Sequential or conformationalSequential or conformational
Accessible, hydrophilic, mobile, usually on the surface or could be exposed as a result of physicochemical change
Binding to antibody:
Kd 10-7 – 10-11 M (high affinity)
Rapid on-rate, variable off-rate
Types of protein-protein interactions (PPI)
Obligate PPI
usually permanent
the protomers are not found as stable structures on their
own in vivo
Non-obligate PPI
Obligate heterodimer
Human cathepsin D
Non-obligate transient homodimer, Sperm lysin (interaction is broken and
formed continuously)
Permanent
(most enzyme-inhibitor complexes)
dissociation constant Kd = [A] [B] / [AB]
10-7 ÷ 10-13 M
Transient
Weak
(electron transport
complexes)
Kd mM-M
Non-obligate permanent
heterodimer
Thrombin and rodniin inhibitor
Intermediate
(antibody-antigen, TCR-MHC-peptide, signal transduction PPI), Kd M-nM
Strong
(require a molecular trigger to shift the
oligomeric equilibrium)
Kd nM-fM
Bovine G protein dissociates into G and G subunits upon GTP, but forms a stable trimer upon GDP
B cell (magenta, orange) and T cell epitopes (blue, green, red) of hen egg-white lysozyme
PDB: 1dpx
Immune Epitope Database and Analysis Resource
IEDB, the newly developed public database by the LIAI together with the SAIC, UCSD, and Denmark University and sponsored by the NIH, maintains experimental data on immune epitopes (the sites on foreign molecules that are recognized by the immune system) curated from literature and submitted from the research community and provides analytical tools for epitope data analysis and their prediction in proteomes.
Agenda
• Introduction to basic concepts of immunological
bioinformatics.
• Overview of the Immune Epitope Database (IEDB).
• Case study #1. Prediction of peptide-MHC binding (Peters et al. A
community resource benchmarking predictions of peptide binding to MHC-I
molecules. PLoS Comput Biol. 2006 Jun 9;2(6):e65): data compilation and
prediction methods evaluation.
• Case study #2. 3D structure based prediction of antibody
binding sites in proteins: data compilation and prediction
methods evaluation.
The MHC class I pathway
Antigen Presenting Cell
Proteasome
Antigen
Peptides
ER
MHC I TCD8+
T-cell epitope
Performance measures for prediction methods
TP
FP
FN
TN
threshold
sensitivity = TP / (TP + FN) = 6/7= 0.86
specificity = TN / (TN + FP) = 6/8 = 0.75
ROC curve
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 0.2 0.4 0.6 0.8 1
False positive rate, FP / (FP + TN)
Tru
e p
osit
ive r
ate
, T
P /
(T
P +
F
N)
AROC
Prediction of MHC class I epitopes
• Gibbs sampling
• Sequence motifs, matrices• Sequence weighted matrices: performance of the method
(measured as AROC) depends on the number of training peptides (”Immunological Bioinformatics” O. Lund, 2005)
• Hidden Markov Models
• Artificial Neural Networks
For T-cell epitopes the most selective requirement is the ability to bind an MHC with high affinity.
ALAKAAAAM
ALAKAAAAN
ALAKAAAAV
ALAKAAAAT
GMNERPILT
GILGFVFTM
TLNAWVKVV
KLNEPVLLL
AVVPFIVSV
Peptides known to bind to the HLA-A*0201 molecule.
0.65
0.7
0.75
0.8
0.85
0.9
0.95
2 10 20 100 200 500
Number of training peptides
Aro
c
Assembling the dataset of measured peptide affinities to MHC class I molecules
(Peters et al. A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput Biol. 2006 Jun 9;2(6):e65)
• Data: pairs {peptide – affinity value in terms of IC50 nM} for a given MHC
allele
• 48 different mouse, human, macaque, and chimpanzee MHC class I alleles.
• Length pf peptides 8 – 11 aa.
• If affinities for the same peptide to the same MHC molecule were recorded
in multiple assays, the geometric mean of the IC50 values was taken.
• 84% of peptides differ in at least two residues with every other peptide in
the dataset.
• 48,828 data points collected from two experimental groups.
An example of the problem of pooling experimental data from different sources
• There is a good agreement between the measured affinity values by two experimental groups (Sette and Buus) for intermediate- and low-affinity peptides, less for high-affinity peptides.
• For peptides with high affinity of 50 nM or better the Matthews correlation coefficient is below 0.37.
• Important message: Pooling experimental data from different sources requires additional validation.
High affinity Low affinity (IC50 500 nM – non-binder)
Peptide binding to MHC class I affinity prediction methods comparison (the same training and test data sets)
Correlation coefficients (ARB=0.55, SMM=0.62, ANN=0.69) are significantly different (p<0.05 using a t test).
Aroc values (ARB=0.934, SMM=0.952, ANN=0.957) are significantly different (p<0.05 using a paired t test on Aroc values generated by bootstrap).
Peptide binding to MHC class I affinity prediction methods comparison.
Prediction performance as a function of training set size.
• Ideally the comparison should be done using ‘blind’ test set excluding every peptide used for any method training. Otherwise the performance of a method can be overestimated.
• That was not done in the discussed work of Peters et al.
Peptide binding to MHC class I affinity prediction methods comparison
(external tools: different training data sets)
Agenda
• Introduction to basic concepts of immunological
bioinformatics.
• Overview of the Immune Epitope Database (IEDB).
• Case study #1. Prediction of peptide-MHC binding (Peters et al. A
community resource benchmarking predictions of peptide binding to MHC-I
molecules. PLoS Comput Biol. 2006 Jun 9;2(6):e65): data compilation and
prediction methods evaluation.
• Case study #2. 3D structure based prediction of antibody
binding sites in proteins: data compilation and prediction
methods evaluation.
HIV-1 envelope protein gp120 core complexed with CD4 and a neutralizing human antibody 17b
The entry of HIV into cells requires the sequential interaction of the viral exterior envelope glycoprotein, gp120, with the CD4 glycoprotein and a chemokine receptor on the cell surface. These interactions initiate a fusion of the viral and cellular membranes. Although gp120 can elicit virus-neutralizing antibodies, HIV eludes the immune system. Antibody 17b
(Fab fragment)
HIV-1 envelope protein gp120 (core fragment)
CD4 (N-terminal two domain fragment)
17b epitope
PDB: 1gc1
17b epitope is comprised of four discontinuous -strands.
Why is the knowledge of antibody epitopes is so important?
• Vaccine design (immunogenicity, i.e. ability of vaccine to elicit in the naïve individual the production of pathogen neutralizing antibodies, is required):
“HIV vaccine design and the neutralizing antibody problem” Nature Immun., 2004, 5, 233
For fusion with its target cells, HIV-1 uses a trimeric Env complex containing gp120 and gp41 subunits.
There are known four broadly reactive and neutralizing anti-HIV mAbs (NAbs):
b12 (epitope on gp120),
2G12 (epitope on gp120,
2F5 (epitope on gp41),
4E10 (epitope on gp41).
Other known mAbs, 447-52D and 58.2 (‘V3 loop Abs’), 17b, and X5 (‘CD4i Abs’) have limited activity.
Strategies for design immunogens that elicit broadly neutralizing antibodies
(from “HIV vaccine design and the neutralizing antibody problem” Nature Immunology, 2004, 5, 233)
To produce molecules that mimic the mature trimer Env on the
virion surface. These molecules can be recombinant or expressed
on the surface of particles such as pseudovirions or
proteoliposomes.
To produce Env molecules engineered to better present NAb
epitopes than do “wild-type” molecules.
To generate stable intermidiates of the entry process with the goal
of exposing conserved epitopes to which antibodies could gain
access during entry.
To produce epitope mimics of the broadly NAbs determined from
structural studies of antibody-antigen complexes.
The best precision in identification of antibody epitopes is provided by X-ray crystallography.
Epitope identification
Other methods to predict structure and location of antibody epitopes include:
- mass spectrometry combined with immunoaffinity procedures;
- screening of combinatorial phage-display peptide libraries;
- mimitope approach: selection ligands from a library of random combinatorial ligands;
- alanine scan;
- etc.
Methods for antibody epitope prediction
• Sequence-based (suitable for linear epitopes only)• Amino acid scales: hydrophobicity, secondary structure (beta-turn),
polarity, flexibility, solvent accessibility etc.• The combination of scales and experimentation with several machine
learning algorithms showed little improvement over single scale-based methods.
• Maximum sensitivity is 59%.
• Structure-based (antibody binding site prediction for a protein of a given 3D structure):
• CEP• DiscoTope
• Epitope mapping using peptide libraries
• Sensitivity = TP / (TP + FN) - a proportion of correctly predicted epitope residues (TP) with respect to the total number of epitope residues (TP+FN).
• Specificity = 1- FP / (TN + FP) – a proportion of correctly predicted non-epitope residues (TN) with respect to the total number of non-epitope residues (TN+FP).
• Positive predictive value (PPV) = TP / (TP + FP) - a proportion of correctly predicted epitope residues (TP) with respect to the total number of predicted epitope residues (TP+FN).
Performance measures for patch prediction methodsPerformance measures for patch prediction methods
PatchDock (best model of 10first)PatchDock (1st model)
PPI-PRED (best patch of 3)
PPI-PRED (1st patch)
ProMate
Protein docking methods (DOT and PatchDock) in comparison with protein-protein binding site prediction methods (PPI-PRED and ProMate) give better PPV at the same level of specificity.
PatchDock (best model of 10first)PatchDock (1st model)
PPI-PRED (best patch of 3)
PPI-PRED (1st patch)
ProMate
Epitope prediction methods (CEP and DiscoTope) show worse correlation between sensitivity and ppv than other methods (e.g. linear correlation coefficient r for CEP is 0.48, for DiscoTope (-7.7) is 0.51, whereas r for PPI-PRED is 0.65, for CLusPro is 0,88 and PatchDock is 0.91).